🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

277 results for “combination” Clear

  1. A trial to learn if AZD9829 is safe and works alone and in combination with other treatments for participants with certain blood cancers.

    AstraZeneca AB

    CD123-Positive Hematological Malignancies: Module 1 focuses on R/R Acute Myeloid Leukemia and R/R Myelodysplastic Syndrome.

    phase 1 other active

    1 trial

  2. AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)

    Amgen

    Thoracic tumors with homozygous MTAP-deletion

    phase 1 other active

    1 trial

  3. AMG 193 in Combination with Other Therapies in Subjects with Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous MTAP-deletion – Master Protocol

    Amgen

    Gastrointestinal tract, biliary tract, or pancreatic cancers with homozygous methylthioadenosine phosphorylase (MTAP)-deletion

    phase 1 other active

    1 trial

  4. AMG 410 Alone and in Combination with other agents in Participants with KRAS Altered Advanced or Metastatic Solid Tumors

    Amgen

    KRAS Altered Advanced or Metastatic Solid Tumors

    phase 1 other active

    1 trial

  5. Adoptive TIL therapy in combination with chemoimmunotherapy in advanced NSCLC patients

    Disc Medicine

    Respiratory tract diseases

    phase 1 other active

    1 trial

  6. An Open-Label Multicenter Phase 1b Study of Tolinapant (ASTX660) in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Patients With Rectum Cancer (PRAAR 1: Preoperative Radiotherapy And ASTX660 in Rectum Cancer)

    The George Institute

    Neoadjuvant therapy in locally-advanced rectal cancer

    phase 1 other active

    1 trial

  7. An Open-label, Single-group, Three-period, Fixed-sequence, Phase I Study to Assess the Pharmacokinetics of AZD6793 Tablets When Administered Alone and in Combination with Itraconazole Capsules in Healthy Adult Female and Male Participants

    AstraZeneca AB

    Chronic obstructive pulmonary disease

    phase 1 other active

    1 trial

  8. An early Phase 1b Study to assess how safe and effective is the treatment with drugs, called Mosunetuzumab or Glofitamab in Combination with drugs called, CC-220 and CC-99282 in Patients with B-Cell Non-Hodgkin Lymphoma.

    Hoffmann-La Roche

    Non-Hodgkin Lymphoma

    phase 1 other active

    1 trial

  9. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover bioequivalence study comparing Trametinib tablets 2 mg, Manufactured by Sun Pharmaceutical Industries Limited, India with MEKINIST® (Trametinib) tablets 2 mg, Distributed by: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936, USA in healthy, adult, human subjects under fasting condition.

    Lacuna Pharma Pty Ltd

    Adjuvant treatment of BRAF V600E or V600K mutation-positive melanoma (in combination with dabrafenib);, BRAF V600E mutation-positive unresectable or metastatic solid tumors;, BRAF V600E mutation-positive metastatic non-small cell lung cancer (NSCLC), in combination with dabrafenib;, BRAF V600E mutation-positive low-grade glioma (LGG)., BRAF V600E mutation-positive locally advanced or metastatic anaplastic thyroid cancer (ATC);, BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma, as a single agent in BRAF-inhibitor treatment-naïve patients or in combination with dabrafenib;

    phase 1 other active

    1 trial

  10. An open-label, randomized, single-dose, two-period, two-treatment, crossover bioequivalence study with GP-IMP-001 in healthy male volunteers under fasting conditions.

    Lacuna Pharma Pty Ltd

    inteneded for treatment of - active rheumatoid arthritis in adult patients, - polyarthritic forms of severe, active juvenile idiopathic arthritis, when the response to nonsteroidal anti-inflammatory drugs has been inadequate, - severe recalcitrant disabling psoriasis which is not adequately responsive to other forms of therapy and severe psoriatic arthritis in adult patients, - mild-to-moderate Crohn’s disease, either alone or in combination with corticosteroids, in adult patients refractory or intolerant to thiopurines.

    phase 1 other active

    1 trial

  11. Arm B: A combination of pentoxifylline and tocopherol acetate in addition to best standard care [a structured programme of rehabilitation exercises] for 6 months

    United Therapeutics Europe Ltd

    Head and Neck Fibrosis

    phase 1 other completed

    1 trial

  12. Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination

    Atea Pharmaceuticals

    Healthy Volunteer Study

    phase 1 small molecule active

    1 trial

  13. Bioequivalence study of the oral suspension of netupitant/palonosetron combination product versus the hard capsules of netupitant/palonosetron combination product after a single dose administration to healthy male and female volunteers in an open-label, randomised, single centre, 2-treatment, 4-period, 2 sequence replicative design

    Helsinn Birex Pharmaceuticals

    Healthy volunteers

    phase 1 other active

    1 trial

  14. Bupivacaine alone OR Bupivacaine-Ketorolac-Ketamine (BKK) Combination

    Rhythm Pharmaceuticals Netherlands B.V.

    Pain Management

    phase 1 small molecule active

    1 trial

  15. CLEVER PEPTIDE : Open-label, non-controlled, multicenter, dose escalation, first-in-human clinical trial to evaluate the safety, pharmacokinetics and preliminary antitumor activity of intravenous PEP-010, administered as single agent and in combination with paclitaxel or with gemcitabine in patients with recurrent and/or metastatic solid cancer

    The George Institute

    Patients with recurrent and/or metastatic solid cancer.

    phase 1 other active

    1 trial

  16. Clinical trial evaluating the safety, tolerability, and preliminary efficacy of BNT116 alone and in combinations in patients with advanced non-small cell lung cancer

    BioNTech SE

    Advanced non-small cell lung cancer

    phase 1 other active

    1 trial

  17. Debio 0123 in combination with carboplatin and etoposide in adult participants with small cell lung cancer that recurred or progressed after platinum-based therapy.

    Alphapharm Pty Ltd

    Small cell lung cancer

    phase 1 other active

    1 trial

  18. Evaluating Bioequivalence of a Fixed Dose Combination versus Individual Tablets of Bempedoic Acid / Ezetimibe, and Atorvastatin.

    Daiichi Sankyo

    No medical condition.

    phase 1 other active

    1 trial

  19. Evaluating Bioequivalence of a Fixed Dose Combination versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Atorvastatin.

    Daiichi Sankyo

    No medical condition.

    phase 1 other active

    1 trial

  20. Evaluating Bioequivalence of a Fixed Dose Combination versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Rosuvastatin.

    Daiichi Sankyo

    No medical condition

    phase 1 other active

    1 trial

  21. Evaluating Bioequivalence of a Fixed Dose Combination versus Tablets of Bempedoic Acid / Ezetimibe and Rosuvastatin.

    Daiichi Sankyo

    No medical condition.

    phase 1 other active

    1 trial

  22. Evaluation of safety, side effects and how the inhaled drug CHF10073 is absorbed, modified and removed from the body when administered alone or in combination with itraconazole in male and female healthy adults

    Chiesi Farmaceutici S.p.A

    Pulmonary fibrosis

    phase 1 other active

    1 trial

  23. Fimasartan/Atorvastatin Combination Tablet

    Yung NA

    Hypertension

    phase 1 small molecule completed

    1 trial

  24. First time in human (FTIH) study to investigate the safety and preliminary activity of GSK5533524 alone or in combination in adult participants with advanced solid tumors

    GlaxoSmithKline

    Neoplasms

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources